PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-14.34%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-7.72%
Operating expenses reduction while Biotechnology median is 0.92%. Seth Klarman would investigate advantages.
-7.72%
Total costs reduction while Biotechnology median is 0.62%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
7.65%
EBITDA change of 7.65% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
7.72%
Income change of 7.72% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
158.44%
Other expenses change of 158.44% versus flat Biotechnology. Walter Schloss would verify control.
12.50%
Income change of 12.50% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Income change of 12.50% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
15.94%
EPS change of 15.94% versus flat Biotechnology. Walter Schloss would verify quality.
15.94%
Diluted EPS change of 15.94% versus flat Biotechnology. Walter Schloss would verify quality.
4.10%
Share count reduction below 50% of Biotechnology median of 0.16%. Jim Chanos would check for issues.
4.10%
Diluted share reduction below 50% of Biotechnology median of 0.16%. Jim Chanos would check for issues.